The historical rank and industry rank for Bio-Path Holdings's Pretax Margin % or its related term are showing as below:
BPTH's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -127.47 * Ranked among companies with meaningful Pretax Margin % only.
Bio-Path Holdings Pretax Margin % Historical Data
The historical data trend for Bio-Path Holdings's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Path Holdings's Pretax Margin %
For the Biotechnology subindustry, Bio-Path Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bio-Path Holdings Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Bio-Path Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BPTH has been successfully added to your 